Please login to the form below

Not currently logged in
Email:
Password:

hepatocellular carcinoma

This page shows the latest hepatocellular carcinoma news and features for those working in and with pharma, biotech and healthcare.

AstraZeneca’s Imfinzi and tremelimumab show unprecedented survival rate in liver cancer patients

AstraZeneca’s Imfinzi and tremelimumab show unprecedented survival rate in liver cancer patients

This was compared to the use of sorafenib as a first-line therapy for patients diagnosed with unresectable hepatocellular carcinoma (HCC) who were both ineligible for localised treatment and had not

Latest news

More from news
Approximately 2 fully matching, plus 60 partially matching documents found.

Latest Intelligence

  • Making Europe a leader in bioscience: boosting trust and opening minds Making Europe a leader in bioscience: boosting trust and opening minds

    This public-private research alliance is aimed at improving survival rates in hepatocellular carcinoma (the primary cancer of the liver).

  • Chinese biotech’s global ambitions Chinese biotech’s global ambitions

    Tislelizumab is in global phase III trials in a number of tumour types, including non-small cell lung cancer, hepatocellular carcinoma and oesophageal squamous cell carcinoma. ... It’s also in phase II trials in patients with previously treated

  • Deal Watch March 2016 Deal Watch March 2016

    Collaboration – discovery, development &commercialisation. $965. Exelixis/ Ipsen. Cabozantinib (Renal Cell Carcinoma, Hepatocellular Carcinoma, other indications) and Cometriq (medullary thyroid cancer).

  • Medius Deal Watch table for April 2015 Medius Deal Watch table for April 2015

    120. 4SC AG/Menarini. Licensing and development agreement. Resminostat (oral HDAC) for hepatocellular carcinoma.

  • Pharma deals in April 2015 Pharma deals in April 2015

    deacetylase (HDAC) inhibitor in all oncological indications, in particular hepatocellular carcinoma in Asia Pacific (excluding Japan).

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides powerful, insight-driven, healthcare communication services to the pharmaceutical industry across the globe, with a focus...

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....